1h Free Analyst Time
According to the recently published report 'Nociceptin Receptor - Drugs In Development, 2022'; Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) pipeline Target constitutes close to 15 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. Speak directly to the analyst to clarify any post sales queries you may have.
Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Nociceptin receptor also known as the nociceptin or orphanin FQ receptor or kappa-type-3 opioid receptor is a protein encoded by the OPRL1 (opioid receptor-like 1) gene. NOP receptors are located both pre- and post-synaptically in various areas of CNS. The nociceptin receptor (NOP) and its endogenous ligand, nociceptin are involved in biological functions, such as pain, anxiety, learning, and memory.
The report 'Nociceptin Receptor - Drugs In Development, 2022' outlays comprehensive information on the Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 3, 6 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Genito Urinary System And Sex Hormones and Undisclosed which include indications Pain, Substance (Drug) Abuse, Diabetic Neuropathic Pain, Neuropathic Pain (Neuralgia), Overactive Bladder, Peripheral Neuropathic Pain, Somatic Pain, Alcohol Addiction, Cancer Pain, Cognitive Impairment, Drug Addiction, Dyskinesia, Fibromyalgia (Fibromyalgia Syndrome), Inflammatory Pain, Insomnia, Low Back Pain, Osteoarthritis Pain, Post-Operative Pain, Post-Traumatic Stress Disorder (PTSD) and Unspecified.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1)
- The report reviews Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Report Coverage
- Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Overview
- Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Companies Involved in Therapeutics Development
- Astraea Therapeutics LLC
- Centrexion Therapeutics Corp
- Dart NeuroScience LLC
- Grunenthal GmbH
- Imbrium Therapeutics LP
- Recordati SpA
- Trigemina Inc
- Tris Pharma Inc
- Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Drug Profiles
- AT-121 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- AT-200 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- AT-312 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- AT-403 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- cebranopadol - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CNTX-3001 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- NOP - Drug Profile
- Product Description
- Mechanism Of Action
- NOP Peripheral - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Peptides to Agonize ORL1 for Acute Pain - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- REC-0438 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecules to Agonize Nociceptin Receptor for Post Traumatic Stress Disorder - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules To Agonize Nociceptin Receptors For Alcohol Addiction - Drug Profile
- Product Description
- Mechanism Of Action
- sunobinop tosylate - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- TI-004 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- TI-006 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Dormant Products
- Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Discontinued Products
- Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Product Development Milestones
- Featured News & Press Releases
- Sep 29, 2021: First participants enrolled in Clinical Trial with Nociceptin/Orphanin peptide receptor (NOP) agonist
- Dec 16, 2020: Peripheral NOP agonist addressing chronic peripheral neuropathic pain enters clinical development
- Aug 28, 2020: Imbrium Therapeutics presents first data and describes novel mechanism of action for IMB-115, a potential first-in-class treatment for insomnia disorder, at 34th Annual Sleep Meeting
- Oct 16, 2019: Imbrium Therapeutics announces first patient dosed in phase 2 study of potential first-in-class molecule for insomnia associated with Alcohol Cessation
- Jun 25, 2019: Imbrium Therapeutics advances insomnia pipeline through initiation of a phase 2 study of potential first-in-class molecule for insomnia associated with alcohol cessation
- Aug 29, 2018: Scientists take big step toward finding non-addictive pain killer
- Sep 30, 2016: Grunenthal’s cebranopadol, a novel strong analgesic, meets primary efficacy endpoint in Phase 3 trial in cancer pain
- Aug 09, 2016: NIH Grant Will Fund Development of Small Molecules for Post-Traumatic Stress Disorder
- May 23, 2016: Cebranopadol Data Presented at World Institute of Pain Congress Highlight Clinically Significant Reductions in Pain, Low Abuse Potential and a Favorable Respiratory Profile
- Feb 29, 2016: Cebranopadol Top-Line Data From Phase IIb Trial in Chronic Lower Back Pain Demonstrate Clinically and Statistically Significant Improvements in Pain Across All Arms
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indication, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products under Investigation by Universities/Institutes, 2022
- Products under Investigation by Universities/Institutes, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Pipeline by Astraea Therapeutics LLC, 2022
- Pipeline by Centrexion Therapeutics Corp, 2022
- Pipeline by Dart NeuroScience LLC, 2022
- Pipeline by Grunenthal GmbH, 2022
- Pipeline by Imbrium Therapeutics LP, 2022
- Pipeline by Recordati SpA, 2022
- Pipeline by Trigemina Inc, 2022
- Pipeline by Tris Pharma Inc, 2022
- Dormant Products, 2022
- Dormant Products, 2022 (Contd..1)
- Discontinued Products, 2022
List of Figures
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Top 10 Indications, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Astraea Therapeutics LLC
- Centrexion Therapeutics Corp
- Dart NeuroScience LLC
- Grunenthal GmbH
- Imbrium Therapeutics LP
- Recordati SpA
- Trigemina Inc
- Tris Pharma Inc
